Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cell & Gene Therapy
Pharma
FDA revisits CAR-T boxed warning on secondary cancers: Marks
“We are in the process ... of reevaluating the need for the current labeling on these products,” Peter Marks, M.D., Ph.D., said of the warnings.
Angus Liu
Nov 1, 2024 10:30am
Roche's Vabysmo will rise above Eylea biosim threat, exec says
Oct 23, 2024 11:24am
Legend sheds GenScript as its majority shareholder
Oct 23, 2024 7:26am
Canadian CDMO OmniaBio debuts new cell and gene therapy facility
Oct 17, 2024 9:25am
AstraZeneca-CSPC, Astellas and more—Fierce Pharma Asia
Oct 11, 2024 9:48am
WuXi service providers eye asset sales amid BIOSECURE threat: FT
Oct 3, 2024 9:47am
More News
J&J, Legend's Carvykti shows 45% survival benefit in myeloma
Sep 30, 2024 9:50am
Daiichi, Fosun, Yuhan and more—Fierce Pharma Asia
Sep 27, 2024 10:15am
BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
Sep 25, 2024 10:52am
Bluebird bio lays off 25% of workforce
Sep 24, 2024 10:19am
See more stories